It's All Relative for This Biotech Underperformer
Earnings season is off and running, and that means many golden opportunities to check in with the most important stocks in the health care industry.
With new U.S. health care policies going into effect, pressures from European austerity pressuring sales in the Old World, and large but often uncertain opportunities presented in developing markets, there's a lot of noise to distract investors from company-specific dynamics at work.
In the following video, health care bureau chief Brenton Flynn tries to cut through the noise and offers some of his key takeaways from last week's Amgen earnings report.
One of the most exciting stocks in the biotech space is Celgene. With its broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.
The article It's All Relative for This Biotech Underperformer originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.